PT  - JOURNAL ARTICLE
AU  - Lederman, Lynne
ED  - Sekeres, Mikkael
TI  - AZA Plus LEN or VOR Do Not Improve Response Rates in MDS or CMML, Though DFS and OS Still an Open Question
DP  - 2014  01
TA  - MD Conference Express
PG  - 13--14
VI  - 14
IP  - 55
4099  - http://mdc.sagepub.com/content/14/55/13.short
4100  - http://mdc.sagepub.com/content/14/55/13.full
AB  - Patients with myelodysplastic syndrome and chronic myelomonocytic leukemia, particularly those with high risk disease, have an unmet therapeutic need. Azacitidine monotherapy results in a modest response rate and duration of response. The addition of vorinostat or lenalidomide to azacytidine does not improve overall response rates, but may improve disease-free survival, does increase toxicity, discontinuations, and dose-reductions.